223 related articles for article (PubMed ID: 35798234)
1. Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series.
Duah M; Beshay M
Int J Infect Dis; 2022 Sep; 122():953-956. PubMed ID: 35798234
[TBL] [Abstract][Full Text] [Related]
2.
Zhang T; Du J; Dong L; Wang F; Zhao L; Jia J; Wang C; Cheng M; Yu X; Huang H
Microbiol Spectr; 2023 Feb; 11(1):e0323822. PubMed ID: 36475850
[TBL] [Abstract][Full Text] [Related]
3. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.
Rizzo AR; Moniri NH
BMC Infect Dis; 2022 Nov; 22(1):874. PubMed ID: 36419143
[TBL] [Abstract][Full Text] [Related]
4. Omadacycline therapy for Mycobacterium abscessus species infections.
Ingram PR; Jones EE; Allen B; Murray RJ; Keehner TJ; Whitmore TJ
Intern Med J; 2023 Dec; 53(12):2257-2263. PubMed ID: 36917124
[TBL] [Abstract][Full Text] [Related]
5. Clinical aspects in patients with pulmonary infection caused by mycobacteria of the Mycobacterium abscessus complex, in the Brazilian Amazon.
Monteiro JTC; Lima KVB; Barretto AR; Furlaneto IP; Gonçalves GM; Costa ARFD; Lopes ML; Dalcolmo MP
J Bras Pneumol; 2018 Apr; 44(2):93-98. PubMed ID: 29791556
[TBL] [Abstract][Full Text] [Related]
6. Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates
Nicklas DA; Maggioncalda EC; Story-Roller E; Eichelman B; Tabor C; Serio AW; Keepers TR; Chitra S; Lamichhane G
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0170421. PubMed ID: 34662184
[TBL] [Abstract][Full Text] [Related]
7.
Kaushik A; Ammerman NC; Martins O; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962331
[TBL] [Abstract][Full Text] [Related]
8. Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease.
Rimal B; Panthi CM; Xie Y; Belz DC; Ignatius EH; Lippincott CK; Deck DH; Serio AW; Lamichhane G
Tuberculosis (Edinb); 2024 May; 146():102482. PubMed ID: 38364332
[TBL] [Abstract][Full Text] [Related]
9. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.
Singh S; Wang JY; Heysell SK; McShane PJ; Wadle C; Shankar P; Huang HL; Pasipanodya J; Boorgula GD; Philley JV; Gumbo T; Srivastava S
Int J Antimicrob Agents; 2023 Jul; 62(1):106847. PubMed ID: 37187338
[TBL] [Abstract][Full Text] [Related]
10. Omadacycline for the Treatment of
Pearson JC; Dionne B; Richterman A; Vidal SJ; Weiss Z; Velásquez GE; Marty FM; Sax PE; Yawetz S
Open Forum Infect Dis; 2020 Oct; 7(10):ofaa415. PubMed ID: 33094118
[TBL] [Abstract][Full Text] [Related]
11. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.
Bax HI; de Vogel CP; Mouton JW; de Steenwinkel JEM
J Antimicrob Chemother; 2019 Oct; 74(10):2930-2933. PubMed ID: 31236595
[TBL] [Abstract][Full Text] [Related]
12.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288634
[TBL] [Abstract][Full Text] [Related]
13. Treatment Approaches to Mycobacterium abscessus Pulmonary Disease.
Holt MR; Baird T
Clin Chest Med; 2023 Dec; 44(4):785-798. PubMed ID: 37890916
[TBL] [Abstract][Full Text] [Related]
14.
Fujiwara K; Aono A; Asami T; Morimoto K; Kamada K; Morishige Y; Igarashi Y; Chikamatsu K; Murase Y; Yamada H; Takaki A; Mitarai S
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0157922. PubMed ID: 37154742
[TBL] [Abstract][Full Text] [Related]
15. Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches.
Kwon YS; Daley CL; Koh WJ
Expert Rev Respir Med; 2019 Sep; 13(9):851-861. PubMed ID: 31256694
[No Abstract] [Full Text] [Related]
16. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease.
Rimal B; Nicklas DA; Panthi CM; Lippincott CK; Belz DC; Ignatius EH; Deck DH; Serio AW; Lamichhane G
mSphere; 2023 Apr; 8(2):e0066522. PubMed ID: 36912629
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD010004. PubMed ID: 32521055
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.
Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N
BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic treatment for nontuberculous mycobacterial lung disease.
Kang YA; Koh WJ
Expert Rev Respir Med; 2016; 10(5):557-68. PubMed ID: 26967761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
